News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novavax, Inc. (NVAX) To Host Conference Call To Discuss Second Quarter 2014 Financial Results On August 6, 2014


7/30/2014 4:12:51 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., July 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will report its financial results for the second quarter of 2014 on Wednesday, August 6, 2014, after market close.

In addition, management will host a conference call, to discuss the quarterly financial results and provide an update on corporate activities. Conference call details are as follows:

Date: August 6, 2014
Time: 4:30 PM US eastern time
Dial-in number: 1 (877) 212-6076 (domestic) or 1 (707) 287-9331 (international)
Via Web: www.novavax.com

Conference call Replay:

Dates: Starting at 6:31pm on August 6, 2014 until midnight October 6, 2014
Dial-in number: 1 (855) 859-2056 (domestic) or 1 (404) 537-3406 (international)
Passcode: 82216889
Via-Web: www.novavax.com , "Investor Info"/"Events"

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000

Novavax logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES